PDF herunterladen
Anästhesiol Intensivmed Notfallmed Schmerzther 2002; 37(3): 125-137
DOI: 10.1055/s-2002-21805
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Anästhesie bei neuromuskulären Erkrankungen
Teil 2: Spezielle Krankheitsbilder

Anesthesia in Neuromuscular Disorders. Part 2: Specific DisordersC.  P.  Baur1, 2 , U.  Schara3 , R.  Schlecht1 , M.  Georgieff1 , F.  Lehmann-Horn2
  • 1 Universitätsklinik für Anästhesiologie der Universität Ulm
  • 2 Abteilung für Angewandte Physiologie der Universität Ulm
  • 3 Klinik für Kinder und Jugendmedizin der Ruhr-Universität Bochum im St. Josef-Hospital
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
12. März 2002 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Neuromuskuläre Erkrankungen können in 4 Hauptgruppen unterteilt werden: die Motoneuronerkrankungen, die peripheren Neuropathien, die Transmissionsstörungen und die Myopathien, die die größte Gruppe bilden. Bei den Motoneuronerkrankungen ergeben sich Probleme hauptsächlich aufgrund der respiratorischen Probleme und der Prädisposition zu Aspirationen bedingt durch die fortschreitende Muskelschwäche. Depolarisierende Muskelrelaxanzien können myotone Reaktionen und massive Hyperkaliämien auslösen, gegenüber nicht depolarisierenden Muskelrelaxanzien besteht hingegen eine extreme Überempfindlichkeit. Bei den peripheren Neuropathien stehen kardiale Einschränkungen im Vordergrund, wobei autonome Regulationsstörungen die kardiovaskuläre Instabilität noch verstärken können. Auf negativ inotrope Effekte der Anästhetika muss daher besonders geachtet werden. Bei höhergradigen AV-Blockierungen kann der Einsatz eines Schrittmachers erforderlich sein. Beim Charcot-Marie-Tooth-Syndrom besteht eine erhöhte Sensitivität auf Thiopental. Die Transmissionsstörungen machen sich in erster Linie durch respiratorische Probleme bemerkbar. Die fluktuierende Schwäche der Bulbär- und Atemmuskulatur kann zu Schluckstörungen, rezidivierenden Aspirationen bis hin zu respiratorischen Insuffizienz führen. Aufgrund der reduzierten Anzahl der Acetylcholinrezeptoren kommt es zu einer stark erhöhten Empfindlichkeit gegenüber nicht depolarisierenden Muskelrelaxanzien, z. T. auch zu einem verminderten Ansprechen auf Succinylcholin. Zu beachten ist, dass verschiedene Medikamente (z. B. Antibiotika, β-Blocker u. a.), die die neuromuskuläre Übertragung verschlechtern, bei diesen Patienten zu einer erheblichen Verstärkung der Symptome führen können. Bei den progressiven Muskeldystrophien wird das anästhesiologische Risiko weitgehend durch die häufigen kardialen und pulmonalen Einschränkungen bestimmt. Succinylcholin birgt ein hohes Risiko eines hyperkaliämischen Herzstillstandes. Patienten mit einer metabolischen Myopathie sind besonders durch den Mitbefall des Myokards gefährdet, respiratorische Probleme sind hier seltener. Der Muskelstoffwechsel sollte mit entsprechender Substratgabe (je nach Krankheitsbild) unterstützt werden. Bei den Membranstörungen können Muskelrigidität (myotone Reaktion) oder -schwäche zu respiratorischer Insuffizienz führen. Neben depolarisierenden Relaxanzien können auch Cholinesterase-Inhibitoren und, je nach Krankheitsbild, auch Hypothermie und Erniedrigung oder Erhöhung des Serum-Kaliumspiegels myotone Reaktionen auslösen.

Abstract

The neuromuscular disorders described are divided into four groups: motoneuron diseases, peripheral neuropathies, disturbances of neuromuscular transmission and myopathies. In motoneuron diseases problems mainly result from respiratory insufficiency and the predisposition for aspiration caused by progressive muscular weakness. Depolarising muscle relaxants may elicit myotonic reaction and massive hyperkalemia. In contrast to non-depolarising muscle relaxants there may be an extreme hypersensitivity. In peripheral neuropathies the cardiac function is often limited whereby dysautonomia may enhance cardiovascular instability. The negative inotropic effect of anaesthetic agents must be observed with care and patients with higher degree of AV blocks may need a cardiac pacemaker during general anaesthesia. The Charcot-Marie-Tooth-Syndrom is characterized with a high sensitivity to thiopental. Disturbances of neuromuscular transmission frequently cause respiratory problems The fluctuating weakness of bulbar and respiratory muscles may impair swallowing and can lead to recurrent aspirations. Due to the reduced number of acetylcholine receptors the sensitivity to non-depolarizing muscle relaxants is elevated and the response to succinylcholine is reduced. Drugs reducing neuromuscular transmission such as antibiotics and β-blockers may enhance these symptoms and should be avoided. In progressive muscular dystrophies the anaesthetic risk is mainly dependent on cardiac and respiratory impairment. Administration of succinylcholine leads to the risk of hyperkalmic cardiac arrest. Patients with metabolic myopathies are also at risk due to the involvement of cardiac muscle but respiratory problems are less frequent. Muscle metabolism should be supported by administration of substrates depending on the underlying disorder. In membrane disorders muscle rigidity (myotonic reactions) or weakness may lead to respiratory insufficiency. In addition to the depolarising muscle relaxants also anticholinesterase drugs, hypothermia and dyskalaemia can evoke myotonic reactions.

Schlüsselwörter

Myopathie - Herzversagen - Respiratorische Insuffizienz - Maligne Hyperthermie - Anästhesierisiko

Key words

Myopathy - Cardiac failure - Respiratory insufficiency - Malignant hyperthermia - Anaesthetic risk

Literatur

  • 1 Rosenbaum K J, Neigh J L, Strobel G E. Sensitivity to nondepolarizing muscle relaxants in amyotrophic lateral sclerosis: report of two cases.  Anesthesiology. 1971;  35 638-641
    PubMedGoogle Scholar
  • 2 Albers J W, Wald J J. Neuroanesthesia and neuromuscular diseases. In: Albin MS (ed) Neuroanesthesia. New York; McGraw-Hill 1997: 453-499
    Google Scholar
  • 3 Azar I. The response of patients with neuromuscular disorders to muscle relaxants: a review.  Anesthesiology. 1984;  61 173-187
    PubMedGoogle Scholar
  • 4 Flacchino F, Gemma M, Bricchi M, Giombini S, Regi B. Sensitivity to curare in patients with upper and lower motor neurone dysfunction.  Anaesthesia. 1991;  46 980-982
    PubMedGoogle Scholar
  • 5 Beach T P, Stone W A, Hamelberg W. Circulation collapse following succinylcholine: Report of a patient with diffuse lower motoneuron disease.  Anesth Analg. 1971;  50 431
    PubMedGoogle Scholar
  • 6 Cooperman L H. Succinylcholine-induced hyperkalemia in neuromuscular disease.  J Am Med Ass. 1970;  213 1867-1871
    CrossrefPubMedGoogle Scholar
  • 7 Gronert G A, Lambert E H, Theye R A. The response of denervated skeletal muscle to succinylcholine.  Anesthesiology. 1973;  39 13-22
    PubMedGoogle Scholar
  • 8 Shime N, Hosokawa T, Hori Y, Hashimoto T, Miyazaki M. (Anesthetic management of a patient with progressive spinal muscular atrophy).  Masui. 1990;  39 918-920
    PubMedGoogle Scholar
  • 9 Mashio H, Ito Y, Yanagita Y, Fujisawa E, Hada K, Goda Y, Kawahigashi H. (Anesthetic management of a patient with amyotrophic lateral sclerosis).  Masui. 2000;  49 191-194
    PubMedGoogle Scholar
  • 10 Brown D L. Spinal, epidural and caudal anesthesia. In: Miller RD (ed) Anesthesia. 5th Edition. New York; Churchill Livingstone 2000: 1491-1519
    Google Scholar
  • 11 Vandam L D, Dripps R D. Exacerbation of preexisting neurologic disease after spinal anesthesia.  N Engl J Med. 1956;  255 843-849
    PubMedGoogle Scholar
  • 12 Hara K, Sakura S, Saito Y, Maeda M, Kosaka Y. Epidural anesthesia and pulmonary function in a patient with amyotrophic lateral sclerosis.  Anesth Analg. 1996;  83 878-879
    CrossrefPubMedGoogle Scholar
  • 13 Kochi T, Oka T, Mizuguchi T. Epidural anesthesia for patients with amyotrophic lateral sclerosis.  Anesth Analg. 1989;  68 410-412
    PubMedGoogle Scholar
  • 14 Chen L K, Chang Y, Liu C C, Hou W Y. Epidural anesthesia combined with propofol sedation for abdominal hysterectomy in a patient with amyotrophic lateral sclerosis - a case report.  Acta Anaesthesiol Sin. 1998;  36 103-106
    PubMedGoogle Scholar
  • 15 Benumof J L. Anesthesia & Uncommon Diseases. 4th Edition. Philadelphia; Saunders 1998
  • 16 Gyermek L. Increased potency of nondepolarizing relaxants after poliomyelitis.  J Clin Pharmacol. 1990;  30 170-173
    PubMedGoogle Scholar
  • 17 Madrid R, Bradley W G, Davis C J. The peroneal muscular atrophy syndrome. Clinical, genetic, electrophysiological and nerve biopsy studies. Part 2. Observations on pathological changes in sural nerve biopsies.  J Neurol Sci. 1977;  32 91-122
    CrossrefPubMedGoogle Scholar
  • 18 Felice K J, Poole R M, Blaivas M, Albers J W. Hereditary neuropathy with liability to pressure palsies masquerading as slowly progressive polyneuropathy.  Eur Neurol. 1994;  34 173-175
    PubMedGoogle Scholar
  • 19 Mortier W. Muskel- und Nervenerkrankungen im Kindesalter. Stuttgart; Thieme 1994
  • 20 Hara K, Minami K, Takamoto K, Shiraishi M, Sata T. The prolonged effect of a muscle relaxant in a patient with chronic inflammatory demyelinating polyradiculoneuropathy.  Anesth Analg. 2000;  90 224-226
    PubMedGoogle Scholar
  • 21 Brooks H, Christian A S, May A E. Pregnancy, anaesthesia and Guillain Barre syndrome.  Anaesthesia. 2000;  55 894-898
    CrossrefPubMedGoogle Scholar
  • 22 Fitzal S. (Anesthesia in neuromuscular diseases).  Anaesthesist. 1992;  41 730-742
    PubMedGoogle Scholar
  • 23 Zochodne D W. Autonomic involvement in Guillain-Barre syndrome: a review.  Muscle Nerve. 1994;  17 1145-1155
    CrossrefPubMedGoogle Scholar
  • 24 Feldman J M. Cardiac arrest after succinylcholine administrationi n a pregnant patient recovered from Guillain-Barre syndrome.  Anesthesiology. 1990;  72 942-944
    CrossrefPubMedGoogle Scholar
  • 25 McGrady E M. Management of labour and delivery in a patient with Guillain-Barre syndrome.  Anaesthesia. 1987;  42 899
    PubMedGoogle Scholar
  • 26 Steiner I, Argov Z, Cahan C, Abramsky O. Guillain-Barre syndrome after epidural anesthesia: direct nerve root damage may trigger disease.  Neurology. 1985;  35 1473-1475
    CrossrefPubMedGoogle Scholar
  • 27 Plaugher M E. Emergent exploratory laparotomy for a patient with recent Guillain-Barre recurrence: a case report.  AANA J. 1994;  62 437-440
    PubMedGoogle Scholar
  • 28 Winer J B, Hughes R A. Identification of patients at risk of arrhythmia in the Guillain-Barre syndrome.  Q J Med. 1988;  68 735-739
    PubMedGoogle Scholar
  • 29 Albers J W, Kelly J J. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features.  Muscle Nerve. 1989;  12 435-451
    CrossrefPubMedGoogle Scholar
  • 30 Hochman M S, Kobetz S A, Handwerker J V. Inappropriate secretion of antidiuretic hormone associated with Guillain-Barre syndrome.  Ann Neurol. 1982;  11 322-323
    PubMedGoogle Scholar
  • 31 Auer-Grumbach M, Wagner K, Fazekas F, Loscher W N, Strasser-Fuchs S, Hartung H P. Hereditäre motorisch-sensible Neuropathien (Charcot-marie-Tooth Syndrom) und verwandte Neuropathien. Aktuelle Klassifikation und Genotyp-Phänotyp-Korrelation.  Nervenarzt. 1999;  70 1052-1061
    CrossrefPubMedGoogle Scholar
  • 32 Antognini J F. Anaesthesia for Charcot-Marie-Tooth disease: a review of 86 cases.  Can J Anaesth. 1992;  39 398-400
    PubMedGoogle Scholar
  • 33 Kotani N, Hirota K, Anzawa N, Takamura K, Sakai T, Matsuki A. Motor and sensory disability has a strong relationship to induction dose of thiopental in patients with the hypertropic variety of Charcot-Marie-Tooth syndrome.  Anesth Analg. 1996;  82 182-186
    PubMedGoogle Scholar
  • 34 Reah G, Lyons G R, Wilson R C. Anaesthesia for caesarean section in a patient with Charcot-Marie-Tooth disease.  Anaesthesia. 1998;  53 586-588
    CrossrefPubMedGoogle Scholar
  • 35 Naguib M, Samarkandi A H. Response to atracurium and mivacurium in a patient with Charcot-Marie-Tooth disease.  Can J Anaesth. 1998;  45 56-59
    PubMedGoogle Scholar
  • 36 Drachman D B. Myasthenia gravis.  N Engl J Med. 1994;  330 1797-1810
    CrossrefPubMedGoogle Scholar
  • 37 Brown T C, Gebert R, Meretoja O A, Shield L K. Myasthenia gravis in children and its anaesthetic implications.  Anaesth Intensive Care. 1990;  18 466-472
    PubMedGoogle Scholar
  • 38 Foldes F F, McNall P G. Myasthenia gravis.  Anesthesiology. 1962;  23 837
    PubMedGoogle Scholar
  • 39 Hunter J M. New neuromuscular blocking drugs.  N Engl J Med. 1995;  332 1691-1699
    CrossrefPubMedGoogle Scholar
  • 40 Wainwright A P, Brodrick P M. Suxamethonium in myasthenia gravis.  Anaesthesia. 1987;  42 950-957
    PubMedGoogle Scholar
  • 41 Telford R J, Hollway T E. The myasthenic syndrome: anaesthesia in a patient treated with 3.4 diaminopyridine.  Br J Anaesth. 1990;  64 363-366
    PubMedGoogle Scholar
  • 42 Wise R P. A myasthenic syndrome complicating bronchial carcinoma.  Anasthesia. 1962;  17 488-504
    PubMedGoogle Scholar
  • 43 Lohmann-Horn F, Ludwolph A C. Neurologische Therapie. 3. Auflage. München; Urban & Fischer 2001
  • 44 Buzello W, Noeldge G, Krieg N, Brobmann G F. Vecuronium for muscle relaxation in patients with myasthenia gravis.  Anesthesiology. 1986;  64 507-509
    PubMedGoogle Scholar
  • 45 Enoki T, Naito Y, Hirokawa Y, Nomura R, Hatano Y, Mori K. Marked sensitivity to pancuronium in a patient without clinical manifestations of myasthenia gravis.  Anesth Analg. 1989;  69 840-842
    PubMedGoogle Scholar
  • 46 Rowbottom S J. Isoflurane for thymectomy in myasthenia gravis.  Anaesth Intensive Care. 1989;  17 444-447
    PubMedGoogle Scholar
  • 47 Kiran U, Choudhury M, Saxena N, Kapoor P. Sevoflurane as a sole anaesthetic for thymectomy in myasthenia gravis.  Acta Anaesthesiol Scand. 2000;  44 351-353
    CrossrefPubMedGoogle Scholar
  • 48 Granell Gil M, Garcia Aguado R, Ferrandiz Roca L, Arnau Obrer A, Canto Armengood A, Grau Real F, Palanca Sanfrancisco J M. (Fastrach laryngeal mask, sevoflurane and remifentanil: an anesthetic alternative for the myasthenic patient).  Rev Esp Anestesiol Reanim. 2001;  48 85-88
    PubMedGoogle Scholar
  • 49 Kawamata M, Miyabe M, Nakae Y, Sonoda H, Fujimura N, Sumita S, Fujita S, Namiki A. ontinuous thoracic epidural blockade in combination with general anesthesia with nitrous oxide, oxygen, and sevoflurane in two patients with myasthenia gravis).  Masui. 1993;  42 898-901
    PubMedGoogle Scholar
  • 50 Georgiou L, Bousoula M, Spetsaki M. Combined thoracic epidural and general anaesthesia with laryngeal mask airway for laparoscopic cholecystectomy in a patient with myasthenia gravis.  Anaesthesia. 2000;  55 821-822
    PubMedGoogle Scholar
  • 51 Hubler M, Litz R J, Albrecht D M. Combination of balanced and regional anaesthesia for minimally invasive surgery in a patient with myasthenia gravis.  Eur J Anaesthesiol. 2000;  17 325-328
    CrossrefPubMedGoogle Scholar
  • 52 Abel M, Eisenkraft J. Sensitivity to atracurium in myasthenia gravis patients during true remission.  Anesthesiology. 1990;  73 A892
    PubMedGoogle Scholar
  • 53 Argov Z, Mastaglia F L. Drug therapy: Disorders of neuromuscular transmission caused by drugs.  N Engl J Med. 1979;  301 409-413
    PubMedGoogle Scholar
  • 54 Flacke W. Treatment of myasthenia gravis.  N Engl J Med. 1973;  288 27-31
    PubMedGoogle Scholar
  • 55 Chagnac Y, Hadani M, Goldhammer Y. Myasthenic crisis after intravenous administration of iodinated contrast agent.  Neurology. 1985;  35 1219-1220
    PubMedGoogle Scholar
  • 56 O'Neill J H, Murray N M, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases.  Brain. 1988;  111 577-596
    PubMedGoogle Scholar
  • 57 Fadic R, Sunada Y, Waclawik A J, Buck S, Lewandoski P J, Campbell K P, Lotz B P. Brief report: deficiency of a dystrophin-associated glycoprotein (adhalin) in a patient with muscular dystrophy and cardiomyopathy.  N Engl J Med. 1996;  334 362-366
    CrossrefPubMedGoogle Scholar
  • 58 Buckley A E, Dean J, Mahy I R. Cardiac involvement in Emery Dreifuss muscular dystrophy: a case series.  Heart. 1999;  82 105-108
    PubMedGoogle Scholar
  • 59 Barresi R, Di Blasi C, Negri T, Brugnoni R, Vitali A, Felisari G, Salandi A, Daniel S, Cornelio F, Morandi L, Mora M. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations.  J Med Genet. 2000;  37 102-107
    CrossrefPubMedGoogle Scholar
  • 60 Finsterer J, Stollberger C. Cardiac involvement in primary myopathies.  Caridiology. 2000;  94 1-11
    CrossrefPubMedGoogle Scholar
  • 61 de Visser M, de Voogt W G, la Riviere G V. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy.  Muscle Nerve. 1992;  15 591-596
    PubMedGoogle Scholar
  • 62 Laforet P, de Toma C, Eymard B, Becane H M, Jeanpierre M, Fardeau M, Duboc D. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy.  Neurology. 1998;  51 1454-1456
    PubMedGoogle Scholar
  • 63 Fitzsimons R B. Racioscapulohumeral muscular dystrophy.  Curr Opin Neurol. 1999;  12 501-511
    CrossrefPubMedGoogle Scholar
  • 64 Barohn R J, Levine E J, Olson J O, Menddell J R. Gastric hypomotility in Duchenne's muscular dystrophy.  N Engl J Med. 1988;  319 15-18
    PubMedGoogle Scholar
  • 65 Ishikawa Y, Bach J R, Sama R J, Tamura T, Song J, Marra S W, Minami R. Cardiovascular considerations in the management of neuromuscular disease.  Semin Neurol. 1995;  15 93-108
    PubMedGoogle Scholar
  • 66 Shapiro F, Sethna N, Colan S, Wohl M E, Specht L. Spinal fusion in Duchenne muscular dystrophy: a multlidisciplinary approach.  Muscle Nerve. 1992;  15 604-614
    CrossrefPubMedGoogle Scholar
  • 67 Griggs R C, Mendell J R, Miller R G. Evaluation and Treatment of Myopathies. Philadelphia; Oxford University Press 1995
  • 68 Hoogenwaard E M, Bakker E, Ippel P F, Oosterwijk J C, Majoor-Krakauer D F, Leschot N J, Van Essen A J, Brunner H G, van der Wouw P A, Wilde A A, de Visser M. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study.  Lancet. 1999;  353 2116-2119
    CrossrefPubMedGoogle Scholar
  • 69 Funakoshi M, Tsuchiya Y, Arahata K. Emerin and cardiomyopathy in Emery-Dreifuss muscular dystrophy.  Neuromuscul Disord. 1999;  9 108-114
    CrossrefPubMedGoogle Scholar
  • 70 Bush A, Dubowitz V. Fetal rhabdomyolysis complicating general anaesthesia in a child with Becker muscular dystrophy.  Neuromuscul Disord. 1991;  1 201-204
    PubMedGoogle Scholar
  • 71 Breucking E, Reimnitz P, Schara U, Mortier W. Inzidenz schwerer Narkosezwischenfälle bei Patienten und in Familien mit progressiven Muskeldystrophien vom Typ Duchenne und Becker.  Anaesthesist. 2000;  49 187-195
    CrossrefPubMedGoogle Scholar
  • 72 Buzello W, Huttarsch H. Muscle relaxation in patients with Duchenne's muscular dystrophy. Use of vecuronium in two patients.  Br J Anaesth. 1988;  60 228-231
    PubMedGoogle Scholar
  • 73 Diefenbach C, Buzello W. Muskelrelaxation beim neuromuskulär kranken Patienten.  Anaesthesist. 1994;  43 283-288
    CrossrefPubMedGoogle Scholar
  • 74 von zur Muhlen F, Klass C, Kreuzer H, Mall G, Giese A, Reimers C D. Cardiac involvement in paroximal myotonic myopathy.  Heart. 1998;  79 619-621
    PubMedGoogle Scholar
  • 75 Harper P S, Rudel R. Myotonic Disorders. In: Engel AG, Franzini-Armstrong C (ed) Myology. 2nd Edition. New York; McGraw-Hill 1994: 1192-1219
    Google Scholar
  • 76 Lenard H G, Goebel H H, Weigel W. Smooth muscle involvement in congenital myotonic dystrophy.  Neuropadiatrie. 1977;  8 42-52
    PubMedGoogle Scholar
  • 77 Horowitz M, Maddox A, Maddern G J, Wishart J, Collins P J, Shearman D J. Gastric and esophageal emptying in dystrophia myotonica. Effect of metoclopramide.  Gastroenterology. 1987;  92 570-577
    PubMedGoogle Scholar
  • 78 Sarnat H B, Silbert S W. Maturational arrest of fetal muscle in neonatal myotonic dystrophy. A pathologic study of four cases.  Arch Neurol. 1976;  33 466-474
    PubMedGoogle Scholar
  • 79 Bourke T D, Zuck D. Thiopentone in dystrophica myotonia.  Br J Anaesth. 1997;  29 35
    PubMedGoogle Scholar
  • 80 Aldrige L M. Anaesthetic problems in myotonic dystrophy. A case report and review of the Aberdeen experience comprising 48 general anaesthetics in a further 16 patients.  Br J Anaesth. 1985;  57 1119-1130
    PubMedGoogle Scholar
  • 81 Speedy H. Exaggerated physiological responses to propofol in myotonic dystrophy.  Br J Anaesth. 1990;  64 110-112
    PubMedGoogle Scholar
  • 82 Tzabar Y, Marshall R. Myotonic dystrophy and target-controlled propofol infusions.  Br J Anaesth. 1995;  74 108-109
    PubMedGoogle Scholar
  • 83 Hansotia P, Frens D. Hypersomnia associated with alveolar hypoventilation in myotonic dystrophy.  Neurology. 1981;  31 1336-1337
    PubMedGoogle Scholar
  • 84 Mitchell M M, Ali H H, Savarese J J. Myotonia and neuromuscular blocking agents.  Anesthesiology. 1978;  49 44-48
    PubMedGoogle Scholar
  • 85 Breucking E, Mortier W. Anaesthesia in neuromuscular diseases. In: Mortier W, Breucking E (ed) Malignant Hyperthermia. Neuromuscular Disease and Anaesthesia. Stuttgart; Thieme 1990: 61-71
    Google Scholar
  • 86 Buzello W, Krieg N, Schlickewei A. Hazards of neostigmine in patients with neuromuscular disorders. Report of two cases.  Br J Anaesth. 1982;  54 529-534
    PubMedGoogle Scholar
  • 87 Diefenbach C, Lynch J, Abel M, Buzello W. Vecuronium for muscle relaxation in patients with dystrophia myotonica.  Anesth Analg. 1993;  76 872-874
    PubMedGoogle Scholar
  • 88 Anderson B J, Brown T C. congenital myotonic dystrophy in children - a review of ten years' experience.  Anaesth Intensive Care. 1989;  17 320-324
    PubMedGoogle Scholar
  • 89 Harper P S. Myotonic Dystrophy. 2nd Edition. Philadelphia; Saunders 1989
  • 90 Motta J, Guilleminault C, Billingham M, Barry W, Mason J. Cardiac abnormalities in myotonic dystrophy. Electrophysiologic and histopathologic studies.  Am J Med. 1979;  67 467-473
    CrossrefPubMedGoogle Scholar
  • 91 Melacini P, Fanin M, Duggan D J, Freda M P, Berardinelli A, Danieli G A, Barchitta A, Hoffman E P, Dalla Volta S, Angelini C. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations.  Muscle Nerve. 1999;  22 473-479
    CrossrefPubMedGoogle Scholar
  • 92 Griggs R C, Davis R J, Anderson D C, Dove J T. Cardiac conduction in myotonic dystrophy.  Am J Med. 1975;  59 37-42
    CrossrefPubMedGoogle Scholar
  • 93 Grigg L E, Chan W, Mond H G, Vohra J K, Downey W F. Ventricular tachycardia and sudden death in myotonic dystrophy: clinical, electrophysiologic and pathologic features.  J Am Coll Cardiol. 1985;  6 254-256
    PubMedGoogle Scholar
  • 94 Moxley R T, Corbett A J, Minaker K L, Rowe J W. Whole body insulin resistance in myotonic dystrophy.  Ann Neurol. 1984;  15 157-162
    PubMedGoogle Scholar
  • 95 Ricker K. Myotonic dystrophy and proximal myotonic myopathy.  J Neurol. 1999;  246 334-338
    PubMedGoogle Scholar
  • 96 Newman B, Meola G, O'Donovan D G, Schapira A H, Kingston H. Proximal myotonic myopathy (PROMM) presenting as myotonia during pregnancy.  Neuromuscul Disord. 1999;  9 144-149
    CrossrefPubMedGoogle Scholar
  • 97 Lehmann-Horn F. Neuromuscular Disorders and Malignant Hyperthermia.  Anesthesia and Resuscitation. 1994;  30 81-86
    PubMedGoogle Scholar
  • 98 Caccamo D V, Keene C Y, Durham J, Peven D. Fulminant rhabdomyolysis in a patient with dermatomyositis.  Neurology. 1993;  43 844-845
    PubMedGoogle Scholar
  • 99 Hochberg M C, Feldman D, Stevens M B. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature.  Semin Arthritis Rheum. 1986;  15 168-178
    CrossrefPubMedGoogle Scholar
  • 100 Eisele J H. Connective tissue diseases. In: Katz J, Benumof J, Kadis LB (eds) Anesthesia and uncommon diseases. 3rd Edition. Philadelphia; Saunders 1990: 645-667
    Google Scholar
  • 101 Ganta R, Campbell I T, Mostafa S M. Anaesthesia and acute dermatomyositis/polymyositis.  Br J Anaesth. 1998;  60 854-858
    PubMedGoogle Scholar
  • 102 Gottdiener J S, Sherber H S, Hawley R J, Engel W K. Cardiac manifestations in polymyositis.  Am Cardiol. 1978;  41 1141-1149
    PubMedGoogle Scholar
  • 103 Rockelein S, Gebert M, Baar H, Endsberger G. Neuromuskuläre Blockade mit Atracurium bei Dermatomyositis.  Anaesthesist. 1995;  44 442-444
    CrossrefPubMedGoogle Scholar
  • 104 Mair P, Mitterschiffthaler G, Hohlbock E. Neuromuskuläre Blockade mit Vecuronium bei Dermatomyositis.  Anaesthesist. 1989;  38 626-628
    PubMedGoogle Scholar
  • 105 McFarlane H J, Soni N. Pompe's disease and anaesthesia.  Anaesthesia. 1986;  41 1219-1224
    PubMedGoogle Scholar
  • 106 Jerusalem F, Zierz S. Muskelerkrankungen. Klinik - Therapie - Pathologie. 2. Auflage. Stuttgart; Thieme 1991
  • 107 Engel A G. Acid maltase deficiency. In: Engel AG, Franzini-Armstrong C (eds) Myology. 2nd Edition. New York; McGraw-Hill 1994: 1533-1553
    Google Scholar
  • 108 Moufarrej N A, Bertorini T E. Respiratory insufficiency in adult-type acid maltase deficiency.  South Med J. 1993;  86 560-567
    PubMedGoogle Scholar
  • 109 Kotani N, Hashimoto H, Hirota K, Muraoka M, Matsuki A. Prolonged respiratory depression after anesthesia for parathyroidectomy in a patient with juvenile type of acid maltase deficiency.  J Clin Anesth. 1996;  8 620
    CrossrefPubMedGoogle Scholar
  • 110 Samuels T A, Coleman P. McArdle's disease and caesarean section.  Anaesthesia. 1988;  43 161-162
    PubMedGoogle Scholar
  • 111 Slonim A E, Goans P J. Myopathy in McArdle's syndrome. Improvement with a high-protein diet.  N Engl J Med. 1985;  312 355-359
    PubMedGoogle Scholar
  • 112 Rajah A, Bell C F. Atracurium and McArdle's disease.  Anaesthesia. 1986;  41 93
    PubMedGoogle Scholar
  • 113 Tzabar Y, Ross D G. Vecuronium and McArdle's disease.  Anaesthesia. 1990;  45 697
    PubMedGoogle Scholar
  • 114 Casson H. Anaesthesia for portocaval bypass in patients with metabolic diseases.  Br J Anaesth. 1975;  47 969-975
    PubMedGoogle Scholar
  • 115 Shenkman Z, Golub Y, Meretyk S, Shir Y, Landau D, Landau E H. Anaesthetic management of a patient with glycogen storage disease type 1b.  Can J Anaesth. 1996;  43 467-470
    PubMedGoogle Scholar
  • 116 Lucas M, Hinojosa M, Rodriguez A, Garcia-Guasch R. Anaesthesia in lipid myopathy.  Eur J Anaesthesiol. 2000;  17 461-462
    CrossrefPubMedGoogle Scholar
  • 117 Kiechl S, Kohlendorfer U, Paetzke I, Sperl W, Reiner J, Willeit J. Myoglobinurie und Carnitin-Palmitoyl-Transferase-Mangel. Diagnostische Verfahren und Differentialdiagnose.  Wien Klin Wochenschr. 1994;  106 174-177
    PubMedGoogle Scholar
  • 118 Katsuya H, Misumi M, Ohtani Y, Milke T. Postanesthetic acute renal failure due to carnitine palmitoyl transferase deficiency.  Anesthesiology. 1988;  68 945-948
    PubMedGoogle Scholar
  • 119 Campos Suarez J M. (Malignant hyperthermia).  Rev Esp Anestesiol Reanim. 1989;  36 232-239
    PubMedGoogle Scholar
  • 120 Zierz S. Carnitine palmitoyltransferase deficiency. In: Engel AG, Franzini-Armstrong C (eds) Myology. 2nd Edition. New York; McGraw-Hill 1994: 1577-1586
    Google Scholar
  • 121 Angelini C, Vergani L, Martinuzzi A. Clinical and biochemical aspects of carnitine deficiency and insufficiency: transport defects and inborn errors of beta-oxidation.  Crit Rev Clin Lab Sci. 1992;  29 217-242
    PubMedGoogle Scholar
  • 122 Moundras J M, Wattrisse G, Leroy B, Decocq J, Krivosic-Horber R. Ann Fr Anesth Reanim 2000 19: 611-616
  • 123 Fishbein W N, Muldoon S M, Deuster P A, Armbrustmacher V W. Myoadenylate deaminase deficiency and malignant hyperthermia susceptibility: is there a relationship?.  Biochem Med. 1985;  34 344-354
    CrossrefPubMedGoogle Scholar
  • 124 DiMauro S, Moraes C T. Mitochondrial encephalomyopathies.  Arch Neurol. 1993;  50 1197-1208
    PubMedGoogle Scholar
  • 125 Barohn R J, Clanton T, Sahenk Z, Mendell J R. Recurrent respiratory insufficiency and depressed ventilatory drive complicating mitochondrial myopathies.  Neurology. 1990;  40 103-106
    PubMedGoogle Scholar
  • 126 James R H. Thiopentone and ophthalmoplegia plus.  Anaesthesia. 1985;  40 88
    PubMedGoogle Scholar
  • 127 James R H. Induction agent sensitivity and ophthalmoplegia plus.  Anaesthesia. 1986;  41 216
    PubMedGoogle Scholar
  • 128 Breucking E, Mortier W, Lampert R, Brandt L. Anästhesie und Intensivtherapie bei einer Patientin mit mitochondrialer Myopathie.  Anaesthesist. 1993;  42 719-723
    PubMedGoogle Scholar
  • 129 Lauwers M H, Van Lersberghe C, Camu F. Inhalation anaesthesia and the Kearns-Sayre syndrome.  Anaesthesia. 1994;  49 876-878
    PubMedGoogle Scholar
  • 130 Robertson J A. Ocular muscular dystrophy. A cause of curare sensitivity.  Anaesthesia. 1984;  39 251-253
    PubMedGoogle Scholar
  • 131 Lehmann-Horn F, Engel A G, Ricker H, Rüdel R. The Periodic Paralyses and Paramyotonia Congenita. In: Engel AG, Franzini-Armstrong C (eds) Myology. 2nd Edition. New york; McGraw-Hill 1994: 1304-1334
    Google Scholar
  • 132 Rüdel R, Lehmann-Horn F, Ricker K. The Nondystrophic Myotonias. In: Engel AG, Franzini-Armstrong C (eds) Myology. 2nd Edition. New York; McGraw-Hill 1994: 1291-1303
    Google Scholar
  • 133 Venables G S, Bates D, Shaw D A. Hypothyroidism with true myotonia.  N Neurol Neurosurg Psychiatry. 1978;  41 1013-1015
    PubMedGoogle Scholar
  • 134 Egan T J, Klein R. Hyperkalaemic periodic paralysis.  Paediatrics. 1959;  24 761
    PubMedGoogle Scholar
  • 135 Aarons J J, Moon R E, Camporesi E M. General anesthesia and hyperkalemic periodic paralysis.  Anesthesiology. 1989;  71 303-304
    PubMedGoogle Scholar
  • 136 Siler J N, Discavage W J. Anesthetic management of hypokalemic periodic paralysis.  Anesthesiology. 1975;  43 489-490
    PubMedGoogle Scholar
  • 137 Rollman J E, Dickson C M. Anesthetic management of a patient with hypokalemic familial periodic paralysis for coronary artery bypass surgery.  Anesthesiology. 1985;  63 526-527
    PubMedGoogle Scholar
  • 138 Thomas A, Leopold U, Winkler H. Maligne Hyperthermie bei Paramyotonia congenita.  Anaesthesiol Reanim. 1988;  13 295-300
    PubMedGoogle Scholar

Dr. Christoph P. Baur

Universitätsklinik für Anästhesiologie
Universität Ulm

Steinhövelstraße 9

89070 Ulm

eMail: christoph.baur@medizin.uni-ulm.de